HealthDay News — There is a causal association for plasma caffeine concentrations with adiposity and risk for type 2 diabetes, according to a study published online March 14 in BMJ Medicine.
Susanna C. Larsson, PhD, from the Karolinska Institutet in Stockholm, and colleagues conducted a 2-sample Mendelian randomization study using genome-wide association study summary data for 2 single nucleotide polymorphisms associated with plasma caffeine at the genome-wide significance threshold and their association with outcomes among individuals of European ancestry.
The researchers found that higher genetically predicted plasma caffeine concentrations were associated with lower body mass index (beta, −0.08 standard deviation [SD], where 1 SD equals about 4.8 kg/m2 in body mass index, for every SD increase in plasma caffeine) and whole-body fat mass (beta, −0.06 SD, where 1 SD equals about 9.5 kg), but not fat-free mass. In 2 consortia, higher genetically predicted plasma caffeine concentrations were associated with a lower risk for type 2 diabetes (combined odds ratio, 0.81). Overall, 43% of the effect of caffeine on type 2 diabetes was estimated to be mediated via the reduction in body mass index. Genetically predicted plasma caffeine concentrations were not strongly associated with a risk for any of the studied cardiovascular diseases.
“This mendelian randomization study found evidence to support causal associations of higher plasma caffeine concentrations with lower adiposity and risk of type 2 diabetes,” the authors write. “Randomized controlled trials are warranted to assess whether noncaloric caffeine containing beverages might play a role in reducing the risk of obesity and type 2 diabetes.”
One author disclosed financial ties to Novo Nordisk.